Lightrock Netherlands B.V. Acquires 25,465 Shares of Encompass Health Corporation (NYSE:EHC)

Lightrock Netherlands B.V. increased its stake in Encompass Health Corporation (NYSE:EHC - Free Report) by 32.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,006 shares of the company's stock after buying an additional 25,465 shares during the quarter. Encompass Health makes up 2.8% of Lightrock Netherlands B.V.'s holdings, making the stock its 16th biggest position. Lightrock Netherlands B.V. owned about 0.10% of Encompass Health worth $10,450,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the stock. Colonial Trust Co SC acquired a new stake in Encompass Health during the 4th quarter valued at $29,000. Transce3nd LLC acquired a new stake in Encompass Health during the 4th quarter valued at $40,000. CBIZ Investment Advisory Services LLC lifted its holdings in Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock valued at $42,000 after purchasing an additional 127 shares during the last quarter. Signaturefd LLC lifted its holdings in Encompass Health by 21.6% during the 4th quarter. Signaturefd LLC now owns 704 shares of the company's stock valued at $65,000 after purchasing an additional 125 shares during the last quarter. Finally, Arlington Trust Co LLC lifted its holdings in Encompass Health by 22.9% during the 1st quarter. Arlington Trust Co LLC now owns 671 shares of the company's stock valued at $68,000 after purchasing an additional 125 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.

Insider Activity

In related news, EVP John Patrick Darby sold 10,000 shares of the company's stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the sale, the executive vice president owned 79,710 shares in the company, valued at approximately $9,149,910.90. This represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the sale, the chief executive officer owned 527,070 shares of the company's stock, valued at $64,054,817.10. This trade represents a 18.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 132,663 shares of company stock worth $16,034,082 over the last quarter. 2.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Barclays lifted their target price on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Wall Street Zen downgraded Encompass Health from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Royal Bank Of Canada lifted their target price on Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. Stephens upgraded Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price target on the stock in a research report on Thursday, June 5th. Finally, UBS Group raised their price target on Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Encompass Health has an average rating of "Buy" and an average target price of $127.00.

Encompass Health Trading Up 0.1%

Shares of Encompass Health stock traded up $0.16 during midday trading on Friday, reaching $119.04. The company had a trading volume of 400,752 shares, compared to its average volume of 702,585. The stock has a fifty day moving average price of $119.39 and a 200 day moving average price of $105.53. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market cap of $12.00 billion, a PE ratio of 24.60, a P/E/G ratio of 2.42 and a beta of 0.88. Encompass Health Corporation has a fifty-two week low of $82.74 and a fifty-two week high of $123.13.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.63% and a net margin of 8.97%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period in the previous year, the firm earned $1.12 earnings per share. The company's revenue was up 10.6% compared to the same quarter last year. On average, equities analysts anticipate that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.57%. Encompass Health's dividend payout ratio is 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.